Fiduciary Alliance LLC Buys 1,714 Shares of Amgen Inc. $AMGN

Fiduciary Alliance LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 6.2% during the first quarter, HoldingsChannel.com reports. The fund owned 29,414 shares of the medical research company’s stock after buying an additional 1,714 shares during the quarter. Fiduciary Alliance LLC’s holdings in Amgen were worth $10,243,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Kestra Private Wealth Services LLC lifted its position in Amgen by 8.3% during the first quarter. Kestra Private Wealth Services LLC now owns 79,323 shares of the medical research company’s stock valued at $27,910,000 after purchasing an additional 6,063 shares during the period. Cardano Risk Management B.V. bought a new stake in Amgen in the 1st quarter worth approximately $96,659,000. Norway Savings Bank grew its position in Amgen by 0.7% in the 1st quarter. Norway Savings Bank now owns 4,734 shares of the medical research company’s stock worth $1,666,000 after purchasing an additional 33 shares during the period. Ritholtz Wealth Management raised its stake in Amgen by 6.6% during the 1st quarter. Ritholtz Wealth Management now owns 15,454 shares of the medical research company’s stock valued at $5,438,000 after buying an additional 960 shares during the last quarter. Finally, Breakwater Capital Group lifted its holdings in shares of Amgen by 1.4% during the 1st quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after buying an additional 29 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 1.3%

NASDAQ:AMGN opened at $351.64 on Thursday. Amgen Inc. has a one year low of $269.77 and a one year high of $391.29. The business has a fifty day moving average price of $340.45 and a 200-day moving average price of $345.95. The firm has a market capitalization of $189.78 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 3.48 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the business earned $4.90 earnings per share. Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts forecast that Amgen Inc. will post 22.38 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Thursday, June 18th. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Wells Fargo & Company increased their target price on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. UBS Group raised their target price on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $354.42.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.